139 related articles for article (PubMed ID: 33328738)
41. Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report.
Wu Z; Zhang Z; Zhang D; Li Z
Front Oncol; 2024; 14():1357230. PubMed ID: 38476366
[TBL] [Abstract][Full Text] [Related]
42. Synchronous driver gene alterations (EGFR L858R, T790M, and ROS1) rearrangements in a patient with early-stage lung adenocarcinoma.
Masago K; Kuroda H; Takahashi Y; Oya Y; Sasaki E; Sakakura N; Matsushita H
Cancer Genet; 2022 Nov; 268-269():124-127. PubMed ID: 36332423
[TBL] [Abstract][Full Text] [Related]
43. Driver gene alterations in lung adenocarcinoma: Demographic features of 2544 Chinese cases.
Hu M; Zhang T; Yang Y; Che N; Li J; Liu Z; Li B
Int J Biol Markers; 2020 Dec; 35(4):44-50. PubMed ID: 33063618
[TBL] [Abstract][Full Text] [Related]
44. A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.
Zhang X; Jiang Y; Yu H; Xia H; Wang X
World J Surg Oncol; 2020 Jul; 18(1):172. PubMed ID: 32677962
[TBL] [Abstract][Full Text] [Related]
45. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
[TBL] [Abstract][Full Text] [Related]
46. Surgical treatment is an effective approach for patients with synchronous multiple primary lung cancers.
Peng Y; Ren W; Wang H; Li M; Feng Z; Peng Z
J Cancer Res Ther; 2017; 13(4):702-706. PubMed ID: 28901318
[TBL] [Abstract][Full Text] [Related]
47. ctDNA facilitated the diagnosis of a patient with synchronous urothelial carcinoma and non-small cell lung cancer: case report.
Qian C; Dai N; Xu M; Luo H; Feng Y; Zhang M; Chen R; Wang D
Ann Transl Med; 2020 Oct; 8(20):1323. PubMed ID: 33209903
[TBL] [Abstract][Full Text] [Related]
48. [The characteristics of lung adenocarcinoma driver gene variants detected by high-throughput sequencing and quantitative fluorescence PCR].
Chen LF; Chen XY; Lin J; Yu XB; Jin L
Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):772-778. PubMed ID: 31594041
[No Abstract] [Full Text] [Related]
49. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
50. Long-Term Clinical Benefit in
Ye J; Ma Y; Ou Q; Yan J; Ye B; Li Y
Front Oncol; 2022; 12():883367. PubMed ID: 35692748
[TBL] [Abstract][Full Text] [Related]
51. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
52. [The effective mutation of epidermal growth factor receptor in synchronous multiple primary lung cancers: study of clinical, radiographic and pathological factors].
Wang YJ; Feng H; Ma SR; Wang YC; Liu YY; Bai HJ; Zhao L
Zhonghua Yi Xue Za Zhi; 2019 Aug; 99(29):2297-2301. PubMed ID: 31434406
[No Abstract] [Full Text] [Related]
53. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
54. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
55. Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.
Zhu YC; Liao XH; Wang WX; Xu CW; Zhuang W; Wei JG; Du KQ
Thorac Cancer; 2018 Feb; 9(2):324-327. PubMed ID: 29251824
[TBL] [Abstract][Full Text] [Related]
56. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
[TBL] [Abstract][Full Text] [Related]
57. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
[TBL] [Abstract][Full Text] [Related]
58. Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers.
Tessema M; Rossi MR; Picchi MA; Yingling CM; Lin Y; Ramalingam SS; Belinsky SA
Lung Cancer; 2018 Sep; 123():99-106. PubMed ID: 30089603
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study.
Song Y; Jia Z; Wu P; Wang W; Ou Q; Bao H; Yu M; Wu X; Liu P; Liang N; Zhang S; Li S
BMC Pulm Med; 2020 Apr; 20(1):80. PubMed ID: 32245453
[TBL] [Abstract][Full Text] [Related]
60. The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.
Cao L; Long L; Li M; Yang H; Deng P; Mao X; Xiang J; Li B; Zhang T; Hu C
Onco Targets Ther; 2018; 11():2637-2646. PubMed ID: 29780256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
